clinical trial · NCT06798727
Evaluation Safety and Explore Efficacy Long-term Follow-up Study on Subjects Receiving SMUP-IA-01 or Active Control
Knee OsteoarthritisSMUP-IA-01(low-dose)SMUP-IA-01(mid-dose)High Hyal Plus
brief summary
This is a follow-up study to investigate the long-term safety and explore efficacy of SMUP-IA-01, for the treatment of Knee Osteoarthritis. Subjects who participated in and completed the initial stage of the Phase II trial (NCT05182034) will be followed-up until 60 months.
started
Mar 20, 2023
primary completion
Mar 20, 2027
completion
Nov 30, 2027
last updated
Feb 7, 2025
detailed description
The subjects will be followed up at 12-month, 24-month, 36-month, 48-month and 60-month after the initial administration of SMUP-IA-01.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol